Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Domino's Pizza, Inc. (DPZ) Price & Performance

ADMA Biologics IncTrade
Domino's Pizza, Inc.Trade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs Domino's Pizza, Inc. — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Domino's Pizza, Inc. trades at $357.34 (market cap $11.51B). The key difference: Domino's Pizza, Inc. is far larger — about 5.3× ADMA Biologics Inc's market cap, and Domino's Pizza, Inc. pays a 2.29% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.

ADMADPZ
Market Cap
$2.18B$11.51B
Sector
HealthConsumer Cyclical
52-Week High
$20.38$467.30
52-Week Low
$7.60$282.89
Enterprise Value
$2.25B$16.47B
Dividend Yield
2.29%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.

Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.

Domino's Pizza, Inc.

DPZ trades at $350.95, down 2.09% on the day, with a bullish technical signal supported by moving averages and ADX. The company reported Q2 2026 EPS of $4.07, missing estimates, but revenue growth remains steady, with 2025 revenue at $4.94B and net income of $601.70M. Recent news highlights Domino's beta testing a new website and app with customer incentives, while institutional positions show mixed adjustments.

The outlook is mixed: analyst consensus is a Moderate Buy with a $371.67 price target, implying upside, but near-term risks include weaker ticket trends, margin pressure from rising costs, and consecutive EPS misses. High debt levels and insider selling add caution, though operational cash flow strength and brand initiatives support long-term potential.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Domino's Pizza, Inc.

Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.

Read more on DPZ